Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1347 - Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: a retrospective study in Spanish population

Date

11 Sep 2017

Session

Poster display session

Topics

Pathology/Molecular Biology;  Breast Cancer

Presenters

Sara Perez Ramirez

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

S. Perez Ramirez1, M. del Monte-Millán2, S. López-Tarruella2, I. Márquez-Rodas2, Y. Jerez2, F. Lobo Samper3, Y. Izarzugaza Peron3, N. Martínez Jañez4, J.A. García-Saenz5, F. Moreno Antón5, P. Zamora Auñón6, M. Arroyo Yustos7, M.Á. Lara Álvarez8, E.M. Ciruelos Gil9, L. Manso Sánchez9, M.J. Echarri González10, J.A. Guerra Martínez11, C. Jara Sánchez12, V. Valentín Maganto13, M. Martin Jimenez14

Author affiliations

  • 1 Medical Oncology, Hospital General Universitario Gregorio Marañon. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 - Madrid/ES
  • 2 Medical Oncology, Hospital General Universitario Gregorio Marañon. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid/ES
  • 3 Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid/ES
  • 4 Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 5 Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid/ES
  • 6 Medical Oncology, Hospital Universitario La Paz, Madrid/ES
  • 7 Medical Oncology, Hospital Universitario Príncipe de Asturias, Madrid/ES
  • 8 Medical Oncology, Hospital Universitario Infanta Leonor, Madrid/ES
  • 9 Medical Oncology, Hospital Universitario 12 de Octubre, Madrid/ES
  • 10 Medical Oncology, Hospital Universitario Severo Ochoa, Madrid/ES
  • 11 Medical Oncology, Hospital Universitario de Fuenlabrada, Madrid/ES
  • 12 Medical Oncology, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Madrid/ES
  • 13 Former Regional Oncology Coordinator, Ministry of Health, Madrid/ES
  • 14 Medical Oncology, Hospital General Universitario Gregorio Marañon. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid/ES
More

Resources

Abstract 1347

Background

Semiquantitative inmunohistochemical (IHC) expression of progesterone receptor (PR) adds prognostic value to the current IHC-based luminal A (LA) definition, such that patients (pts) with LA (Ki67  20%) tumors can be spared from adjuvant chemotherapy (CT). Oncotype Dx® (ODX) and MammaPrint® (MP) assays have been validated as predictors of CT benefit. This study assessed the distribution of recurrence risk in LA and LB breast tumors as defined by Ki67 and PR.

Methods

A retrospective analysis was performed in 889 T1-2, N0-Nmic, M0 tumors for which ODX or MP results and local pathology data were available. Ki67 was assessed by IHC (high ≥14% and low 20%). Histological grade was defined using the Nottingham grading system.

Results

Median age 54 years (18-77). All pts had HER2 negative tumors. Median tumor size 15 mm (2-88). Three hundred (33.7%) tumors were classified as LA and 589 (66.3%) as LB. Grade 1 tumors were higher in LA (27%) than in LB (19%) pts (p 

Conclusions

There is a wide distribution of recurrence risk results between LA and LB tumors defined by Ki67 and PR which confirms the important role of gene-expression assays in adjuvant decision making. Of note about half of pts with LB tumors had low recurrence risk indicating minimal benefit from adjuvant CT.

Clinical trial identification

Legal entity responsible for the study

Ministry of Health of the Community of Madrid (Spain)

Funding

Ministry of Health of the Community of Madrid (Spain)

Disclosure

S. López-Tarruella: Advisory role: Novartis, Pfizer, Celgene. Honoraria/lecturer: Novartis, Pfizer, AstraZeneca, Celgene, Roche. I. Márquez-Rodas: Advisory role: Bristol-Myers Squibb, MSD, Novartis, Roche, Pierre Fabre, Amgen and Bioncotech. M. Martin Jimenez: Holds a patent on the predictive value of the PAM50 gene profile assay. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.